person · Reporting owner

Haviland Kate

Disclosed activity across 4 companies

Tapewire entity: 32613
SEC CIK: 0001663022

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Avalyn Pharma Inc.AVLN · Entity 4662	Director	April 29, 2026	May 01, 2026
Bicara Therapeutics Inc.BCAX · Entity 4673	Director	June 09, 2026	June 10, 2026
Fulcrum Therapeutics, Inc.FULC · Entity 5969	Director	June 30, 2026	July 02, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Avalyn Pharma Inc.

Report date April 29, 2026 · Filed May 01, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.00 · Expires 2036-04-28	Direct	26,978	Reported balance After 2026-04-29 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-04-29 · Grant · Acquired 26,978 · Balance 26,978 F1: 25% of the shares underlying this option vest and become exercisable on September 12, 2025, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: 25% of the shares underlying this option vest and become exercisable on September 12, 2025, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Bicara Therapeutics Inc.

Report date June 09, 2026 · Filed June 10, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.56 · Expires 2036-06-09	Direct	19,475	Reported balance After 2026-06-09 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-09 · Grant · Acquired 19,475 · Balance 19,475 F1: The shares underlying this stock option vest upon the earlier of (i) June 9, 2027 or (ii) the date of the next Annual Meeting of Stockholders of Bicara Therapeutics Inc., subject to the Reporting Person's continued service on such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares underlying this stock option vest upon the earlier of (i) June 9, 2027 or (ii) the date of the next Annual Meeting of Stockholders of Bicara Therapeutics Inc., subject to the Reporting Person's continued service on such vesting date.

Fulcrum Therapeutics, Inc.

Report date June 30, 2026 · Filed July 02, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.66 · Expires 2036-06-29	Direct	32,000	Reported balance After 2026-06-30 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-30 · Grant · Acquired 32,000 · Balance 32,000 F1: This option was granted on June 30, 2026 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service.

Filing footnotes · ownership attribution and instrument terms

F1: This option was granted on June 30, 2026 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Blueprint Medicines Corp

Report date July 17, 2025 · Filed July 21, 2025

Section 16 reporting ended · disclosed 2025-07-21. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Ending reported balance After 2025-07-17 transaction · row 3 3 source rows · reconciled sequence Row 1 · 2025-07-17 · Grant · Acquired 129,210 · Balance 295,139 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F3: Represents shares previously granted to the Reporting Person subject to performance-based vesting conditions ("PSUs"), for which the performance conditions associated with such PSUs had not yet occurred. As of the Effective Time, each PSU was deemed earned based on the greater of target and actual performance as of the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, each PSU was cancelled and automatically converted into the right to receive the Offer Consideration, except that fifty percent of such PSUs that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price, plus one CVR for each share underlying such portion of the award. Row 2 · 2025-07-17 · Disposition to issuer · Disposed 224,410 · Balance 70,729 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F3: Represents shares previously granted to the Reporting Person subject to performance-based vesting conditions ("PSUs"), for which the performance conditions associated with such PSUs had not yet occurred. As of the Effective Time, each PSU was deemed earned based on the greater of target and actual performance as of the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, each PSU was cancelled and automatically converted into the right to receive the Offer Consideration, except that fifty percent of such PSUs that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price, plus one CVR for each share underlying such portion of the award. F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding restricted stock unit ("RSU"), whether vested or unvested, was cancelled and automatically converted into the right to receive the Offer Consideration, except that fifty percent of such RSUs that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price, plus one CVR for each share underlying such portion of the award. Row 3 · 2025-07-17 · Other · Disposed 70,729 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Common Stock held by the Reporting Person was tendered in exchange for the Offer Consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.28	Direct	Reported balance After 2025-07-17 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2025-07-17 · Disposition to issuer · Disposed 2 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F6: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.05	Direct	Reported balance After 2025-07-17 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2025-07-17 · Disposition to issuer · Disposed 591 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F6: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $81.44	Direct	Reported balance After 2025-07-17 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2025-07-17 · Disposition to issuer · Disposed 39,000 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F6: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $86.60	Direct	Reported balance After 2025-07-17 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2025-07-17 · Disposition to issuer · Disposed 32,500 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F6: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $54.13	Direct	Reported balance After 2025-07-17 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2025-07-17 · Disposition to issuer · Disposed 28,500 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F6: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $100.13	Direct	Reported balance After 2025-07-17 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2025-07-17 · Disposition to issuer · Disposed 26,125 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F6: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $61.31	Direct	Reported balance After 2025-07-17 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2025-07-17 · Disposition to issuer · Disposed 80,000 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F6: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $43.15	Direct	Reported balance After 2025-07-17 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2025-07-17 · Disposition to issuer · Disposed 80,000 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F6: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $95.12	Direct	Reported balance After 2025-07-17 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2025-07-17 · Disposition to issuer · Disposed 80,000 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F6: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $96.57	Direct	Reported balance After 2025-07-17 transaction · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · 2025-07-17 · Disposition to issuer · Disposed 70,400 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F6: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser").

F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent.

F3: Represents shares previously granted to the Reporting Person subject to performance-based vesting conditions ("PSUs"), for which the performance conditions associated with such PSUs had not yet occurred. As of the Effective Time, each PSU was deemed earned based on the greater of target and actual performance as of the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, each PSU was cancelled and automatically converted into the right to receive the Offer Consideration, except that fifty percent of such PSUs that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price, plus one CVR for each share underlying such portion of the award.

F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding restricted stock unit ("RSU"), whether vested or unvested, was cancelled and automatically converted into the right to receive the Offer Consideration, except that fifty percent of such RSUs that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price, plus one CVR for each share underlying such portion of the award.

F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Common Stock held by the Reporting Person was tendered in exchange for the Offer Consideration.

F6: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
July 16, 2019 Filed Jul 18, 2019 19:53 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	349	$95.03	$33,165.47	Disclosure SEC source: 0001179110-19-008727 · edgar.xml · nonDerivative · entry 3 Haviland Kate · CIK 0001663022 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,865 F2 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted on April 19, 2019 pursuant to Rule 10b5-1 under the Exchange Act. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.98 to $95.09 per share. Read SEC document
July 16, 2019 Filed Jul 18, 2019 19:53 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	1,222	$95.60	$116,823.20	Disclosure SEC source: 0001179110-19-008727 · edgar.xml · nonDerivative · entry 2 Haviland Kate · CIK 0001663022 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,214 F2 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted on April 19, 2019 pursuant to Rule 10b5-1 under the Exchange Act. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $95.29 to $96.16 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) and (4) to this Form 4. Read SEC document
July 16, 2019 Filed Jul 18, 2019 19:53 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionCommon Stock	11,562	$16.28	$188,229.36	Disclosure SEC source: 0001179110-19-008727 · edgar.xml · nonDerivative · entry 1 Haviland Kate · CIK 0001663022 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,436 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Consists of (i) exercise to acquire 1,571 shares effected pursuant to a trading plan adopted on April 19, 2019 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and (ii) a separate cash exercise to acquire 9,991 shares. Read SEC document
June 17, 2019 Filed Jun 19, 2019 18:08 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionStock Option (Right to Buy) · Derivative	5,666	$0.00 Strike: $36.05	$0.00	Disclosure SEC source: 0001179110-19-007896 · edgar.xml · derivative · entry 10 Haviland Kate · CIK 0001663022 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,334 Underlying: Common Stock · 5,666 shares Expires 2027-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Effected pursuant to a trading plan adopted on April 19, 2019 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F9 · derivative.exercise_date: This option was granted on February 16, 2017. This option vested with respect to 1/48th of the shares underlying the option on March 16, 2017 and as to an additional 1/48th of the shares underlying the option each month thereafter. Read SEC document
June 17, 2019 Filed Jun 19, 2019 18:08 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionStock Option (Right to Buy) · Derivative	6,286	$0.00 Strike: $16.28	$0.00	Disclosure SEC source: 0001179110-19-007896 · edgar.xml · derivative · entry 9 Haviland Kate · CIK 0001663022 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,209 Underlying: Common Stock · 6,286 shares Expires 2026-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Effected pursuant to a trading plan adopted on April 19, 2019 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F8 · derivative.exercise_date: This option was granted on February 1, 2016. This option vested with respect to 25% of the shares underlying the option on January 5, 2017 and as to an additional 1/48th of the shares underlying the option each month thereafter. Read SEC document
June 17, 2019 Filed Jun 19, 2019 18:08 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	2,370	$94.44	$223,822.80	Disclosure SEC source: 0001179110-19-007896 · edgar.xml · nonDerivative · entry 8 Haviland Kate · CIK 0001663022 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,874 F1 · kind: Effected pursuant to a trading plan adopted on April 19, 2019 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F7 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.24 to $94.84 per share. Read SEC document
June 17, 2019 Filed Jun 19, 2019 18:08 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	2,549	$95.53	$243,505.97	Disclosure SEC source: 0001179110-19-007896 · edgar.xml · nonDerivative · entry 7 Haviland Kate · CIK 0001663022 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,244 F1 · kind: Effected pursuant to a trading plan adopted on April 19, 2019 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F6 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.99 to $95.94 per share. Read SEC document
June 17, 2019 Filed Jun 19, 2019 18:08 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	2,977	$96.35	$286,833.95	Disclosure SEC source: 0001179110-19-007896 · edgar.xml · nonDerivative · entry 6 Haviland Kate · CIK 0001663022 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,793 F1 · kind: Effected pursuant to a trading plan adopted on April 19, 2019 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $95.96 to $96.94 per share. Read SEC document
June 17, 2019 Filed Jun 19, 2019 18:08 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	2,123	$97.39	$206,758.97	Disclosure SEC source: 0001179110-19-007896 · edgar.xml · nonDerivative · entry 5 Haviland Kate · CIK 0001663022 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,770 F1 · kind: Effected pursuant to a trading plan adopted on April 19, 2019 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $96.99 to $97.95 per share. Read SEC document
June 17, 2019 Filed Jun 19, 2019 18:08 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	1,000	$98.63	$98,630.00	Disclosure SEC source: 0001179110-19-007896 · edgar.xml · nonDerivative · entry 4 Haviland Kate · CIK 0001663022 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,893 F1 · kind: Effected pursuant to a trading plan adopted on April 19, 2019 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.21 to $99.17 per share. Read SEC document
June 17, 2019 Filed Jun 19, 2019 18:08 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	933	$100.02	$93,318.66	Disclosure SEC source: 0001179110-19-007896 · edgar.xml · nonDerivative · entry 3 Haviland Kate · CIK 0001663022 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,893 F1 · kind: Effected pursuant to a trading plan adopted on April 19, 2019 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $100.00 to $100.23 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (7) of this Form 4. Read SEC document
June 17, 2019 Filed Jun 19, 2019 18:08 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionCommon Stock	5,666	$36.05	$204,259.30	Disclosure SEC source: 0001179110-19-007896 · edgar.xml · nonDerivative · entry 2 Haviland Kate · CIK 0001663022 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,826 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Effected pursuant to a trading plan adopted on April 19, 2019 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Read SEC document
June 17, 2019 Filed Jun 19, 2019 18:08 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionCommon Stock	6,286	$16.28	$102,336.08	Disclosure SEC source: 0001179110-19-007896 · edgar.xml · nonDerivative · entry 1 Haviland Kate · CIK 0001663022 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,160 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Effected pursuant to a trading plan adopted on April 19, 2019 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Read SEC document
March 01, 2019 Filed Mar 5, 2019 17:31 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionStock Option (Right to Buy) · Derivative	7,500	$0.00 Strike: $36.05	$0.00	Disclosure SEC source: 0001179110-19-003315 · edgar.xml · derivative · entry 7 Haviland Kate · CIK 0001663022 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 7,500 shares Expires 2027-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercises reported on this Form 4 was effected pursuant to a trading plan adopted on December 21, 2017 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F8 · derivative.exercise_date: This option was granted on February 16, 2017. This option vested with respect to 1/48th of the shares underlying the option on March 16, 2017 and as to an additional 1/48th of the shares underlying the option each month thereafter. Read SEC document
March 01, 2019 Filed Mar 5, 2019 17:31 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionStock Option (Right to Buy) · Derivative	14,144	$0.00 Strike: $16.28	$0.00	Disclosure SEC source: 0001179110-19-003315 · edgar.xml · derivative · entry 6 Haviland Kate · CIK 0001663022 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,495 Underlying: Common Stock · 14,144 shares Expires 2026-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercises reported on this Form 4 was effected pursuant to a trading plan adopted on December 21, 2017 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F7 · derivative.exercise_date: This option was granted on February 1, 2016. This option vested with respect to 25% of the shares underlying the option on January 5, 2017 and as to an additional 1/48th of the shares underlying the option each month thereafter. Read SEC document
March 01, 2019 Filed Mar 5, 2019 17:31 UTC	Blueprint Medicines Corp BPMC · Entity 77326	GrantRestricted Stock Units · Derivative	8,750	$0.00	$0.00	Disclosure SEC source: 0001179110-19-003315 · edgar.xml · derivative · entry 5 Haviland Kate · CIK 0001663022 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,750 Underlying: Common Stock · 8,750 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F6 · derivative.exercise_date: The restricted stock units vest in four equal annual installments on March 1, 2020, 2021, 2022 and 2023. F6 · derivative.expiration_date: The restricted stock units vest in four equal annual installments on March 1, 2020, 2021, 2022 and 2023. Read SEC document
March 01, 2019 Filed Mar 5, 2019 17:31 UTC	Blueprint Medicines Corp BPMC · Entity 77326	GrantStock Option (Right to Buy) · Derivative	32,500	$0.00 Strike: $86.60	$0.00	Disclosure SEC source: 0001179110-19-003315 · edgar.xml · derivative · entry 4 Haviland Kate · CIK 0001663022 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,500 Underlying: Common Stock · 32,500 shares Expires 2029-03-01 F4 · derivative.exercise_date: This option vests with respect to 1/48th of the shares underlying the option on April 1, 2019 and as to an additional 1/48th of the shares underlying the option each month thereafter. Read SEC document
March 01, 2019 Filed Mar 5, 2019 17:31 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	21,644	$85.05	$1,840,822.20	Disclosure SEC source: 0001179110-19-003315 · edgar.xml · nonDerivative · entry 3 Haviland Kate · CIK 0001663022 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,874 F2 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted on December 21, 2017 pursuant to Rule 10b5-1 under the Exchange Act. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.00 to $85.58 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document
March 01, 2019 Filed Mar 5, 2019 17:31 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionCommon Stock	7,500	$36.05	$270,375.00	Disclosure SEC source: 0001179110-19-003315 · edgar.xml · nonDerivative · entry 2 Haviland Kate · CIK 0001663022 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,518 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercises reported on this Form 4 was effected pursuant to a trading plan adopted on December 21, 2017 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Read SEC document
March 01, 2019 Filed Mar 5, 2019 17:31 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionCommon Stock	14,144	$16.28	$230,264.32	Disclosure SEC source: 0001179110-19-003315 · edgar.xml · nonDerivative · entry 1 Haviland Kate · CIK 0001663022 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,018 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercises reported on this Form 4 was effected pursuant to a trading plan adopted on December 21, 2017 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Read SEC document
March 16, 2018 Filed Mar 20, 2018 20:02 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionStock Option (Right to Buy) · Derivative	2,500	$0.00 Strike: $36.05	$0.00	Disclosure SEC source: 0001179110-18-004708 · edgar.xml · derivative · entry 8 Haviland Kate · CIK 0001663022 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,139 Underlying: Common Stock · 2,500 shares Expires 2027-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercises reported on this Form 4 was effected pursuant to a trading plan adopted on December 21, 2017 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F8 · derivative.exercise_date: This option was granted on February 16, 2017. This option vested with respect to 1/48th of the shares underlying the option on March 16, 2017 and as to an additional 1/48th of the shares underlying the option each month thereafter. Read SEC document
March 16, 2018 Filed Mar 20, 2018 20:02 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionStock Option (Right to Buy) · Derivative	1,571	$0.00 Strike: $16.28	$0.00	Disclosure SEC source: 0001179110-18-004708 · edgar.xml · derivative · entry 7 Haviland Kate · CIK 0001663022 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,639 Underlying: Common Stock · 1,571 shares Expires 2026-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercises reported on this Form 4 was effected pursuant to a trading plan adopted on December 21, 2017 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F7 · derivative.exercise_date: This option was granted on February 1, 2016. This option vested with respect to 25% of the shares underlying the option on January 5, 2017 and as to an additional 1/48th of the shares underlying the option each month thereafter. Read SEC document
March 16, 2018 Filed Mar 20, 2018 20:02 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	571	$99.20	$56,643.20	Disclosure SEC source: 0001179110-18-004708 · edgar.xml · nonDerivative · entry 6 Haviland Kate · CIK 0001663022 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,874 F2 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted on December 21, 2017 pursuant to Rule 10b5-1 under the Exchange Act. F6 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.73 to $99.50 per share. Read SEC document
March 16, 2018 Filed Mar 20, 2018 20:02 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	1,200	$100.02	$120,024.00	Disclosure SEC source: 0001179110-18-004708 · edgar.xml · nonDerivative · entry 5 Haviland Kate · CIK 0001663022 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,445 F2 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted on December 21, 2017 pursuant to Rule 10b5-1 under the Exchange Act. F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.66 to $100.54 per share. Read SEC document
March 16, 2018 Filed Mar 20, 2018 20:02 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	1,800	$101.32	$182,376.00	Disclosure SEC source: 0001179110-18-004708 · edgar.xml · nonDerivative · entry 4 Haviland Kate · CIK 0001663022 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,645 F2 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted on December 21, 2017 pursuant to Rule 10b5-1 under the Exchange Act. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $100.98 to $101.80 per share. Read SEC document
March 16, 2018 Filed Mar 20, 2018 20:02 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	500	$102.19	$51,095.00	Disclosure SEC source: 0001179110-18-004708 · edgar.xml · nonDerivative · entry 3 Haviland Kate · CIK 0001663022 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,445 F2 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted on December 21, 2017 pursuant to Rule 10b5-1 under the Exchange Act. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $101.90 to $102.84 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) through (6) to this Form 4. Read SEC document
March 16, 2018 Filed Mar 20, 2018 20:02 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionCommon Stock	2,500	$36.05	$90,125.00	Disclosure SEC source: 0001179110-18-004708 · edgar.xml · nonDerivative · entry 2 Haviland Kate · CIK 0001663022 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,945 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercises reported on this Form 4 was effected pursuant to a trading plan adopted on December 21, 2017 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Read SEC document
March 16, 2018 Filed Mar 20, 2018 20:02 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionCommon Stock	1,571	$16.28	$25,575.88	Disclosure SEC source: 0001179110-18-004708 · edgar.xml · nonDerivative · entry 1 Haviland Kate · CIK 0001663022 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,445 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercises reported on this Form 4 was effected pursuant to a trading plan adopted on December 21, 2017 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Read SEC document
March 01, 2018 Filed Mar 5, 2018 18:07 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionStock Option (Right to Buy) · Derivative	2,800	$0.00 Strike: $36.05	$0.00	Disclosure SEC source: 0001179110-18-003533 · edgar.xml · derivative · entry 3 Haviland Kate · CIK 0001663022 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,210 Underlying: Common Stock · 2,800 shares Expires 2027-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise reported on this Form 4 was effected pursuant to a trading plan adopted on December 21, 2017 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F4 · derivative.exercise_date: This option was granted on February 16, 2017. This option vested with respect to 1/48th of the shares underlying the option on March 16, 2017 and as to an additional 1/48th of the shares underlying the option each month thereafter. Read SEC document
March 01, 2018 Filed Mar 5, 2018 18:07 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	2,800	$90.00	$252,000.00	Disclosure SEC source: 0001179110-18-003533 · edgar.xml · nonDerivative · entry 2 Haviland Kate · CIK 0001663022 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,874 F2 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted on December 21, 2017 pursuant to Rule 10b5-1 under the Exchange Act. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.00 to $90.02 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document
March 01, 2018 Filed Mar 5, 2018 18:07 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionCommon Stock	2,800	$36.05	$100,940.00	Disclosure SEC source: 0001179110-18-003533 · edgar.xml · nonDerivative · entry 1 Haviland Kate · CIK 0001663022 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,674 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise reported on this Form 4 was effected pursuant to a trading plan adopted on December 21, 2017 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Read SEC document
February 27, 2018 Filed Mar 1, 2018 17:12 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionStock Option (Right to Buy) · Derivative	3,200	$0.00 Strike: $36.05	$0.00	Disclosure SEC source: 0001179110-18-003168 · edgar.xml · derivative · entry 6 Haviland Kate · CIK 0001663022 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,010 Underlying: Common Stock · 3,200 shares Expires 2027-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise reported on this Form 4 was effected pursuant to a trading plan adopted on December 21, 2017 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F7 · derivative.exercise_date: This option was granted on February 16, 2017. This option vested with respect to 1/48th of the shares underlying the option on March 16, 2017 and as to an additional 1/48th of the shares underlying the option each month thereafter. Read SEC document
February 27, 2018 Filed Mar 1, 2018 17:12 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	1,765	$87.70	$154,790.50	Disclosure SEC source: 0001179110-18-003168 · edgar.xml · nonDerivative · entry 5 Haviland Kate · CIK 0001663022 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,874 F2 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted on December 21, 2017 pursuant to Rule 10b5-1 under the Exchange Act. F6 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.08 to $88.05 per share. Read SEC document
February 27, 2018 Filed Mar 1, 2018 17:12 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	1,035	$88.32	$91,411.20	Disclosure SEC source: 0001179110-18-003168 · edgar.xml · nonDerivative · entry 4 Haviland Kate · CIK 0001663022 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,639 F2 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted on December 21, 2017 pursuant to Rule 10b5-1 under the Exchange Act. F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.09 to $88.98 per share. Read SEC document
February 27, 2018 Filed Mar 1, 2018 17:12 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	200	$89.47	$17,894.00	Disclosure SEC source: 0001179110-18-003168 · edgar.xml · nonDerivative · entry 3 Haviland Kate · CIK 0001663022 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,674 F2 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted on December 21, 2017 pursuant to Rule 10b5-1 under the Exchange Act. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.14 to $89.74 per share. Read SEC document
February 27, 2018 Filed Mar 1, 2018 17:12 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	200	$90.70	$18,140.00	Disclosure SEC source: 0001179110-18-003168 · edgar.xml · nonDerivative · entry 2 Haviland Kate · CIK 0001663022 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,874 F2 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted on December 21, 2017 pursuant to Rule 10b5-1 under the Exchange Act. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.65 to $90.75 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) through (6) to this Form 4. Read SEC document
February 27, 2018 Filed Mar 1, 2018 17:12 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionCommon Stock	3,200	$36.05	$115,360.00	Disclosure SEC source: 0001179110-18-003168 · edgar.xml · nonDerivative · entry 1 Haviland Kate · CIK 0001663022 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,074 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise reported on this Form 4 was effected pursuant to a trading plan adopted on December 21, 2017 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Read SEC document
February 16, 2018 Filed Feb 20, 2018 17:31 UTC	Blueprint Medicines Corp BPMC · Entity 77326	GrantStock Option (Right to Buy) · Derivative	39,000	$0.00 Strike: $81.44	$0.00	Disclosure SEC source: 0001179110-18-002408 · edgar.xml · derivative · entry 1 Haviland Kate · CIK 0001663022 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,210 Underlying: Common Stock · 39,000 shares Expires 2028-02-16 F1 · derivative.exercise_date: This option vests with respect to 1/48th of the shares underlying the option on March 16, 2018 and as to an additional 1/48th of the shares underlying the option each month thereafter. Read SEC document
February 12, 2018 Filed Feb 14, 2018 17:23 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionStock Option (Right to Buy) · Derivative	6,775	$0.00 Strike: $16.28	$0.00	Disclosure SEC source: 0001179110-18-002074 · edgar.xml · derivative · entry 7 Haviland Kate · CIK 0001663022 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,210 Underlying: Common Stock · 6,775 shares Expires 2026-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise reported on this Form 4 was effected pursuant to a trading plan adopted on December 20, 2016 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F8 · derivative.exercise_date: This option was granted on February 1, 2016. This option vested with respect to 25% of the shares underlying the option on January 5, 2017 and as to an additional 1/48th of the shares underlying the option each month thereafter. Read SEC document
February 12, 2018 Filed Feb 14, 2018 17:23 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	200	$72.64	$14,528.00	Disclosure SEC source: 0001179110-18-002074 · edgar.xml · nonDerivative · entry 6 Haviland Kate · CIK 0001663022 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,874 F2 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted on December 20, 2016 pursuant to Rule 10b5-1 under the Exchange Act. F7 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.60 to $72.67 per share. Read SEC document
February 12, 2018 Filed Feb 14, 2018 17:23 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	1,476	$73.40	$108,338.40	Disclosure SEC source: 0001179110-18-002074 · edgar.xml · nonDerivative · entry 5 Haviland Kate · CIK 0001663022 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,074 F2 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted on December 20, 2016 pursuant to Rule 10b5-1 under the Exchange Act. F6 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.14 to $73.81 per share. Read SEC document
February 12, 2018 Filed Feb 14, 2018 17:23 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	2,199	$74.58	$164,001.42	Disclosure SEC source: 0001179110-18-002074 · edgar.xml · nonDerivative · entry 4 Haviland Kate · CIK 0001663022 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,550 F2 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted on December 20, 2016 pursuant to Rule 10b5-1 under the Exchange Act. F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.02 to $74.98 per share. Read SEC document
February 12, 2018 Filed Feb 14, 2018 17:23 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	2,000	$75.64	$151,280.00	Disclosure SEC source: 0001179110-18-002074 · edgar.xml · nonDerivative · entry 3 Haviland Kate · CIK 0001663022 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,749 F2 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted on December 20, 2016 pursuant to Rule 10b5-1 under the Exchange Act. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.27 to $76.20 per share. Read SEC document
February 12, 2018 Filed Feb 14, 2018 17:23 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	900	$77.19	$69,471.00	Disclosure SEC source: 0001179110-18-002074 · edgar.xml · nonDerivative · entry 2 Haviland Kate · CIK 0001663022 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,749 F2 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted on December 20, 2016 pursuant to Rule 10b5-1 under the Exchange Act. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.93 to $77.83 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) through (7) to this Form 4. Read SEC document
February 12, 2018 Filed Feb 14, 2018 17:23 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionCommon Stock	6,775	$16.28	$110,297.00	Disclosure SEC source: 0001179110-18-002074 · edgar.xml · nonDerivative · entry 1 Haviland Kate · CIK 0001663022 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,649 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise reported on this Form 4 was effected pursuant to a trading plan adopted on December 20, 2016 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Read SEC document
November 21, 2017 Filed Nov 22, 2017 17:52 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionStock Option (Right to Buy) · Derivative	5,874	$0.00 Strike: $16.28	$0.00	Disclosure SEC source: 0001179110-17-014584 · edgar.xml · derivative · entry 2 Haviland Kate · CIK 0001663022 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,985 Underlying: Common Stock · 5,874 shares Expires 2026-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option was granted on February 1, 2016. This option vested with respect to 25% of the shares underlying the option on January 5, 2017 and as to an additional 1/48th of the shares underlying the option each month thereafter. Read SEC document
November 21, 2017 Filed Nov 22, 2017 17:52 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionCommon Stock	5,874	$16.28	$95,628.72	Disclosure SEC source: 0001179110-17-014584 · edgar.xml · nonDerivative · entry 1 Haviland Kate · CIK 0001663022 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,874 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
October 05, 2017 Filed Oct 10, 2017 17:19 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionStock Option (Right to Buy) · Derivative	5,449	$0.00 Strike: $16.28	$0.00	Disclosure SEC source: 0001179110-17-013229 · edgar.xml · derivative · entry 5 Haviland Kate · CIK 0001663022 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,859 Underlying: Common Stock · 5,449 shares Expires 2026-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise reported on this Form 4 was effected pursuant to a trading plan adopted on December 20, 2016 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F6 · derivative.exercise_date: This option was granted on February 1, 2016. This option vested with respect to 25% of the shares underlying the option on January 5, 2017 and as to an additional 1/48th of the shares underlying the option each month thereafter. Read SEC document
October 05, 2017 Filed Oct 10, 2017 17:19 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	1,261	$65.45	$82,532.45	Disclosure SEC source: 0001179110-17-013229 · edgar.xml · nonDerivative · entry 4 Haviland Kate · CIK 0001663022 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted on December 20, 2016 pursuant to Rule 10b5-1 under the Exchange Act. F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.13 to $65.96 per share. Read SEC document
October 05, 2017 Filed Oct 10, 2017 17:19 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	3,303	$66.58	$219,913.74	Disclosure SEC source: 0001179110-17-013229 · edgar.xml · nonDerivative · entry 3 Haviland Kate · CIK 0001663022 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,261 F2 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted on December 20, 2016 pursuant to Rule 10b5-1 under the Exchange Act. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.98 to $66.97 per share. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.